↓ Skip to main content

A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer

Overview of attention for article published in BMC Cancer, January 2022
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
10 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer
Published in
BMC Cancer, January 2022
DOI 10.1186/s12885-021-09138-z
Pubmed ID
Authors

Soo Jin Park, Suk-Joon Chang, Dong Hoon Suh, Tae Wook Kong, Heekyoung Song, Tae Hun Kim, Jae-Weon Kim, Hee Seung Kim, Sung-Jong Lee

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 2 20%
Researcher 1 10%
Other 1 10%
Student > Doctoral Student 1 10%
Student > Ph. D. Student 1 10%
Other 2 20%
Unknown 2 20%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 2 20%
Psychology 1 10%
Medicine and Dentistry 1 10%
Engineering 1 10%
Unknown 5 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 January 2022.
All research outputs
#20,280,315
of 22,813,792 outputs
Outputs from BMC Cancer
#6,492
of 8,299 outputs
Outputs of similar age
#409,050
of 499,141 outputs
Outputs of similar age from BMC Cancer
#147
of 225 outputs
Altmetric has tracked 22,813,792 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,299 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 499,141 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 225 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.